Results 51 to 60 of about 53,202 (260)

All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium–Glucose Cotransporter-2 Inhibitors

Gastro Hep Advances
Background and Aims: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used in adults with type 2 diabetes (T2D), with or without obesity. The incidence of gastrointestinal (GI) adverse effects (AEs) of GLP-1RA in T2D is unclear.
Samita Garg, Thabet Qapaja, Osama Hamid, Gizem Kaya, Rashid Abdel-Razeq, Dina Alayan, Mohammed Abu-Rumaileh, Anthony Lembo, Steven Nissen   +8 more
doaj   +1 more source

Weight Self‐Stigma and Food Noise During Post‐Metabolic Bariatric Surgery Weight Stability

Obesity, EarlyView.
ABSTRACT Objective Food noise has been studied with GLP‐1‐based therapies, but not with metabolic bariatric surgery (MBS), despite shared mechanisms. Data on food noise beyond initial weight loss are limited, and weight self‐stigma (WSS), which links to poorer weight outcomes and risky behaviors after MBS, may relate to higher food noise, especially ...
Dale S. Bond, Yin Wu, Pavlos K. Papasavas, Michael E. Levin, Rebecca M. Puhl, Dahlia Saad‐Pendergrass, Devika Umashanker, Darren Tishler, Jason Lillis   +8 more
wiley   +1 more source

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Pharmaceuticals, 2022
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun, Zhi-Ming Zheng, Chang-Sheng Shao, Zhi-Yong Zhang, Ming-Wei Li, Li Wang, Han Wang, Gen-Hai Zhao, Peng Wang   +8 more
doaj   +1 more source

Participants baseline characteristics (GLP-1RA cohort, n = 257).

, 2016
Participants baseline characteristics (GLP-1RA cohort, n = 257).
Mike Lonergan (490181), Beverley M. Shields (146725), Ewan R. Pearson (157520), Andrew T. Hattersley (146736), Angus G. Jones (650402), William E. Henley (311559)   +5 more
core   +1 more source

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs

Biomedicines
Cardiovascular–Kidney–Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven by shared pathophysiological mechanisms. However, this framework notably excludes the liver—an organ fundamental to metabolic regulation.
Nikolaos Theodorakis, Maria Nikolaou
openaire   +3 more sources

Glucagon‐Like Peptide‐1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective An increasing number of women of childbearing age worldwide are using glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and are advised to use effective contraception during treatment. Nevertheless, maternity services are encountering increasing numbers of women exposed to GLP‐1 RAs shortly before conception or during pregnancy ...
Katherine G. Y. Lau, Anisha Chopra, Edward Mullins, Rochan Agha‐Jaffar, Tricia Tan, Lynne Sykes, Christina K. H. Yu   +6 more
wiley   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by the 13C breath test or paracetamol absorption technique.
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara, Masato Kasuga   +10 more
doaj   +1 more source

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study

, 2020
BackgroundWe investigated changes in clinical characteristics of SGLT2i and GLP-1RA real-world initiators in Denmark before/after landmark cardiovascular outcome trials.MethodsWe compared first-time SGLT2i (25,070) and GLP-1RA (14,671) initiators to ...
Reimar W. Thomsen (8532312), Henrik T Sørensen, Anastasia Ustyugova (3588770), Larisa Nurkanovic, Maria Lajer (135188), Anastasia Ustyugova, Lisbeth M. Baggesen (8532306), Henrik T. Sørensen (8445630), Jakob S. Knudsen (8532303), Lisbeth M Baggesen, Reimar W Thomsen, Jakob S Knudsen, Larisa Nurkanovic (8532309), Maria Lajer   +13 more
core   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes

Cardiovascular Diabetology
Background Few studies explored the effect of the combination of glucose sodium-cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on the incidence of cardiovascular events in patients with type 2 diabetes (T2D ...
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, Pier Francesco Rambaldi, Carlo Fumagalli, Ludovica Vittoria Marfella, Rosalba La Grotta, Chiara Frigé, Valeria Pellegrini, Davide D’Andrea, Arturo Cesaro, Paolo Calabrò, Carmine Pizzi, Roberto Antonicelli, Antonio Ceriello, Ciro Mauro, Giuseppe Paolisso   +16 more
doaj   +1 more source